Discover
ZVRA
Zevra Therapeutics, Inc.
11.40
3 x 11.38
4 x 11.41
bid
ask
-
0.08
0.65%
01:41 PM
timesize
| Ytd | 27.29% | |
| 1y | -2.52% |
11.34
day range
11.57
7.16
52 week range
15.04
| Open | 11.44 | Prev Close | 11.48 | Low | 11.34 | High | 11.57 | Mkt Cap | 673.92M |
| Vol | 237.04K | Avg Vol | 1.78M | EPS | 1.89 | P/E | 6.03 | Forward P/E | -22.00 |
| Beta | 0.91 | Short Ratio | 6.51 | Inst. Own | 54.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 12.24 | 200-d Avg | 10.11 | 1yr Est | 20.00 |
| Income Statement | |||
| Total Revenue | 39.66M | ||
| Revenues (USD) | 39.66M | ||
| Cost of Revenue | 1.53M | ||
| Gross Profit | 38.14M | ||
| Operating Expenses | 21.36M | ||
| Research and Development Expense | 4.49M | ||
| Selling, General and Administrative Expense | 16.56M | ||
| Operating Income | 16.78M | ||
| Income Tax Expense | 4.04M | ||
| Net Income | 8.75M | ||
| Net Income Common Stock | 8.75M | ||
| Net Income Common Stock (USD) | 8.75M | ||
| Consolidated Income | 8.75M | ||
| Earnings per Basic Share | 0.14 | ||
| Earnings per Basic Share (USD) | 0.14 | ||
| Earnings per Diluted Share | 0.14 | ||
| Earning Before Interest & Taxes (EBIT) | 12.79M | ||
| Earning Before Interest & Taxes (USD) | 12.79M | ||
| Weighted Average Shares | 59.16M | ||
| Weighted Average Shares Diluted | 61.34M | ||
| Balance Sheet | |||
| Cash and Equivalents | 145.32M | ||
| Cash and Equivalents (USD) | 145.32M | ||
| Investments | 114.86M | ||
| Investments Current | 76.25M | ||
| Investments Non-Current | 38.61M | ||
| Trade and Non-Trade Receivables | 22.49M | ||
| Current Assets | 251.30M | ||
| Property, Plant & Equipment Net | 2.31M | ||
| Total Assets | 302.71M | ||
| Debt Current | 626.00K | ||
| Total Debt | 1.50M | ||
| Current Liabilities | 48.63M | ||
| Debt Non-Current | 870.00K | ||
| Total Liabilities | 85.06M | ||
| Accumulated Retained Earnings (Deficit) | -375.42M | ||
| Accumulated Other Comprehensive Income | -2.22M | ||
| Shareholders Equity | 217.65M | ||
| Shareholders Equity (USD) | 217.65M | ||
| Assets Non-Current | 51.41M | ||
| Total Debt (USD) | 1.50M | ||
| Deferred Revenue | 24.88M | ||
| Goodwill and Intangible Assets | 10.49M | ||
| Inventory | 2.45M | ||
| Liabilities Non-Current | 36.43M | ||
| Trade and Non-Trade Payables | 13.96M | ||
| Tax Liabilities | 28.05M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 486.00K | ||
| Net Cash Flow from Financing | 1.59M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 49.73M | ||
| Capital Expenditure | 4.74M | ||
| Issuance (Purchase) of Equity Shares | 435.00K | ||
| Net Cash Flow from Investing | 31.45M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 26.71M | ||
| Net Cash Flow from Operations | 17.03M | ||
| Effect of Exchange Rate Changes on Cash | -342.00K | ||
| Share Based Compensation | 2.97M | ||